Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solid Tumor Rollover Study of adagrasib with or without other cancer therapies
NL-OMON61515Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2026
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adagrasib and pemetrexed in Nonhematologic neoplasms, sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of adverse events. Started Sep 2026; status: recruiting.
02
Drugs
adagrasibpemetrexed
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON61515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61515.